医科学専攻
- Master's Courses
修士課程 - Doctoral Courses
博士課程
Dermatology皮膚科学
STAFF
Professor
-
Asano, YoshihideProfessor. 浅野 善英 教授
Other Faculty / Staff
-
Fujimura, Taku
Associate Professor. 藤村 卓 准教授 -
Takahashi, Takehiro
Lect. 髙橋 岳浩 講師 -
Takahashi, Toshiya
Lect. 髙橋 隼也 講師
CONTACT
TEL:+81-22-717-7271
E-MAIL:tohokudai-hihuka*derma.med.tohoku.ac.jp
(「*」を「@」に変換してください)
OUTLINE
Dermatology is a department that treats all diseases with skin rash. Our research begins with the analysis of skin rashes, but the range of diseases we treat is very broad, and we deal not only with skin diseases but also with systemic diseases involving multiple organ dysfunction. In particular, our research on systemic diseases focuses on the skin as an immune organ and studies the mechanisms by which skin immunity regulates and modifies organ dysfunctions. Currently, we are working on collagen diseases (systemic sclerosis), skin tumors (melanoma, angiosarcoma), inflammatory skin diseases (psoriasis, atopic dermatitis), and pigmentary diseases (vitiligo). The motto of our department is “basic research that can be returned to patients in the future, despite the time it may take,” and we share this awareness throughout the entire laboratory and constantly hold discussions with an awareness of clinical applications. The research mindset fostered in this way has the effect of raising the “resolution of skin rash diagnosis” in actual clinical practice and leads to an enrichment of the time spent as a dermatologist.
皮膚科は皮疹を伴う全ての疾患を扱う診療科です。当科で行う研究は皮疹の解析から始まりますが、扱う疾患の幅は非常に広く、皮膚疾患のみでなく多臓器病変を伴う全身性疾患も扱っています。特に全身性疾患の研究においては、皮膚を免疫臓器として捉え、皮膚免疫が臓器病変を制御・修飾するメカニズムに注目して研究を進めています。
現在取り組んでいる領域として、膠原(こうげん)病(全身性強皮症)、皮膚腫瘍(メラノーマ、血管肉腫)、炎症性皮膚疾患(乾癬(かんせん)、アトピー性皮膚炎)、色素性疾患(白斑)が挙げられます。
当科のモットーは「時間がかかっても将来的に患者さんに還元できる基礎研究」ですが、この意識を研究室全体で共有し、常に臨床応用を意識した議論を重ねています。こうして培われたリサーチマインドは、実臨床において「皮疹を診る解像度」を上げる効果もあり、臨床医として過ごす時間の豊かさの向上にもつながっています。
PCR System
PCRシステムkeyence
蛍光顕微鏡
ARTICLE
Terui H, et al. Staphylococcus aureus skin colonization promotes SLE-like autoimmune inflammation via neutrophil activation and the IL-23/IL-17 axis. Sci Immunol. 7(76): eabm9811, 2022. doi: 10.1126/sciimmunol.abm9811.
Ikawa T, et al. The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts. J Invest Dermatol. 142(6): 1541-1551.e3, 2022. doi: 10.1016/j.jid.2021.10.028.
Ikawa T, et al. Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. Arthritis Res Ther. 23(1): 283, 2021. doi: 10.1186/s13075-021-02667-9.
Ohuchi K, et al. Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas. Exp Dermatol. 2023 Jan;32(1):50-59. doi: 10.1111/exd.14681. Epub 2022 Oct 2. Erratum in: Exp Dermatol. 32(3): 306, 2023.
Amagai R, et al. The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. Int J Mol Sci. 24(1): 875, 2023. doi: 10.3390/ijms24010875.